121 related articles for article (PubMed ID: 6761570)
1. Modulation of the cellular pharmacology and clinical toxicity of 1-beta-D-arabinofuranosylcytosine.
Howell SB; Streifel JA; Pfeifle CE
Med Pediatr Oncol; 1982; 10 Suppl 1():81-91. PubMed ID: 6761570
[TBL] [Abstract][Full Text] [Related]
2. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.
Bhalla K; Swerdlow P; Grant S
Blood; 1991 Dec; 78(11):2937-44. PubMed ID: 1954383
[TBL] [Abstract][Full Text] [Related]
3. Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines.
Kubota M; Takimoto T; Tanizawa A; Akiyama Y; Mikawa H
Biochem Pharmacol; 1988 May; 37(9):1745-9. PubMed ID: 2454114
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity.
Rauscher F; Cadman E
Cancer Res; 1983 Jun; 43(6):2688-93. PubMed ID: 6189585
[TBL] [Abstract][Full Text] [Related]
5. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
6. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology.
Wang LM; White JC; Capizzi RL
Cancer Chemother Pharmacol; 1990; 25(6):418-24. PubMed ID: 2311169
[TBL] [Abstract][Full Text] [Related]
7. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
8. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
9. Bromodeoxyuridine enhancement of 1-beta-D-arabinofuranosylcytosine metabolic activation and toxicity in HL-60 leukemic cells.
Ross DD; Joneckis CC; Song TH; Wu RK
Cancer Res; 1988 Feb; 48(3):517-21. PubMed ID: 3335018
[TBL] [Abstract][Full Text] [Related]
10. Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts.
Snyder RD; Malick NC
Mol Pharmacol; 1985 Dec; 28(6):574-80. PubMed ID: 4079913
[TBL] [Abstract][Full Text] [Related]
11. Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
Fritzer-Szekeres M; Salamon A; Grusch M; Horvath Z; Höchtl T; Steinbrugger R; Jäger W; Krupitza G; Elford HL; Szekeres T
Biochem Pharmacol; 2002 Aug; 64(3):481-5. PubMed ID: 12147300
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
13. Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
Ahlmann M; Lanvers C; Lümkemann K; Rössig C; Freund A; Baumann M; Boos J
Leukemia; 2001 Jan; 15(1):69-73. PubMed ID: 11243402
[TBL] [Abstract][Full Text] [Related]
14. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
Tanaka M; Kimura K; Yoshida S
Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450
[TBL] [Abstract][Full Text] [Related]
16. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
[TBL] [Abstract][Full Text] [Related]
17. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia.
Zittoun R; Zittoun J; Marquet J; Rustum Y; Creaven P
Cancer Res; 1985 Oct; 45(10):5186-92. PubMed ID: 4027995
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.
Streifel JA; Howell SB
Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5132-6. PubMed ID: 6975478
[TBL] [Abstract][Full Text] [Related]
19. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
[TBL] [Abstract][Full Text] [Related]
20. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]